Drug Profile

Gumokimab - Akeso Biopharma

Alternative Names: AK-111

Latest Information Update: 02 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Akeso Biopharma
Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
Mechanism of Action Interleukin 17 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preregistration Plaque psoriasis
Phase III Ankylosing spondylitis

Most Recent Events

26 Aug 2025 Akeso Biopharma announces intention to submit NDA for Ankylosing spondylitis
25 Aug 2025 Efficacy data from a phase III trial in Ankylosing spondylitis released by Akeso Biopharma
06 May 2025 Akeso plans a phase I trial (In volunteers) in China (SC) (NCT06947109)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com